

10th

Canadian Kidney Cancer Forum

FINAL PROGRAM

KCRNC

KIDNEY CANCER RESEARCH
NETWORK OF CANADA

RRCRC

RÉSEAU DE RECHERCHE SUR LE
CANCER DU REIN DU CANADA



#CKCF19

April 11-13, 2019
The Westin Toronto Airport Hotel

Objectives for Forum 2019

The primary meeting objectives are to:

- Increase knowledge of recent developments in the management of renal cell carcinoma;
- Discuss and stimulate new research in kidney cancer nationally and internationally;
- Raise awareness of ongoing research in kidney cancer in Canada;
- Raise awareness of genetic factors predicting kidney cancer;
- Identify future initiatives and projects for the KCRNC;
- Examine recent clinical trial data

THURSDAY, APRIL 11, 2019

1500 - 1800 [Arrival & Registration - Sutton Foyer](#)

1830 - 1930 [Buffet Dinner - Sutton C](#)

SESSION I - HOT TOPICS IN RENAL CELL CARCINOMA

[Session Room: Sutton B](#)

1930 - 1935 [Welcome and Introduction of Program Co-Chairs](#)
Anil Kapoor

1935 - 1945 [Welcome: Overview of Program, Speakers
and Meeting Objectives](#)
Sébastien Hotte, Ricardo Rendon

Introduction/Moderators: Jean-Baptiste Lattouf, Scott North

1945 - 2005 **KEYNOTE LECTURE: CARMENA** and the Role of
Cytoreductive Nephrectomy in 2019
Laurence Albiges

2005 - 2010 Discussion and Q & A

10th

Canadian Kidney Cancer Forum

- 2010 - 2055 **KEYNOTE LECTURE:** Emerging IO-based doublets in mRCC
Brian Rini
- 2055 - 2100 Discussion and Q & A
- 2100 - 2300 [Networking in Hospitality Suite \(1035\).](#)
(all welcome)

FRIDAY, APRIL 12, 2019

- 0700 - 0800 [Buffet Breakfast - Sutton Foyer](#)
- 0700 - 0800 CKCis Operations Committee Meeting
(CKCis site investigators & support staff only)
[Sutton C](#)

SESSION II - TRANSLATIONAL AND GENETIC RESEARCH

[Session Room: Sutton B](#)

Introduction/Moderator: Bimal Bhindi, Simon Tanguay

- 0800 - 0825 Biomarkers in Metastatic RCC: Too Hot, Too Cold,
or Just Right
Aly-Khan Lalani
- 0825 - 0850 **KEYNOTE LECTURE:** 2nd Line Real World Data for IO in RCC
Laurence Albiges
- 0850 - 0915 **KEYNOTE LECTURE:** Germline Testing in Hereditary
Kidney Cancer Syndromes
Mark Ball
- 0915 - 0920 Discussion and Q & A
- 0920 - 0950 Update and Development of 2018 Clinical Research
Mainstreaming Genetics
VHL Database Project Update
Raymond Kim
- 0950 - 0955 Discussion and Q & A

0955 - 1005 Immune-Potentiating Impact of the Gut Microbiome on Kidney Cancer Immune Infiltrate: A Novel Predictor of Immune Checkpoint Inhibitors Response
Bertrand Routy

1005 - 1020 [Health Break - Sutton Foyer](#)
[Poster Viewing - Sutton Lower Foyer](#)

Introduction/Moderator: Rahul Bansal, Christina Canil

1020 - 1030 Identifying Prognostic and Predictive Biomarkers in Metastatic Renal-Cell Carcinoma: An Exploratory Study of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Tissue Biorepository
Shaan Dudani

1030 - 1100 CKCis Update Report: Data, Recent Publications and Ongoing Research
Naveen Basappa, Rodney Breau

1100 - 1105 Discussion and Q & A

1105 - 1130 **KEYNOTE LECTURE:** Neo/Adjuvant Approaches, Translational Gene Expression Data in Localized and mRCC
Brian Rini

1130 - 1135 Discussion and Q & A

Introduction/Moderator: Luke Lavallée, Lori Wood

1135 - 1205 Clinical Trials Update, Opportunities, and Ongoing Projects in Canada
Anil Kapoor (PROSPER)
Danny Heng (non-clear cell RCC)
Christian Kollmannsberger (Other)

1205 - 1210 Discussion and Q & A

- 1210 - 1225 Kidney Cancer Canada Updates
Stephen Andrew, Andrew Weller
- 1225 - 1230 Discussion and Q & A
- 1230 - 1235 [Group Photo - Sutton Lower Foyer](#)
- 1235 - 1330 [Lunch with Exhibitors - Sutton A](#)

SESSION III - OPTIMAL MANAGEMENT OF PRIMARY TUMORS IN RCC

[Session Room: Sutton B](#)

Introduction/Moderators: Rodney Breau, Samantha Gray

- 1330 - 1355 **KEYNOTE LECTURE:** Management of High Risk Cystic Lesions
Michael Blute
- 1355 - 1400 Discussion and Q & A
- 1400 - 1410 Surveillance of Complex Renal Cysts - The SoCRAtiC
Pilot Study
Patrick Richard

RADIATION THERAPY IN KIDNEY CANCER

Introduction/Moderators: Kristen McAlpine, Eric Winquist

- 1410 - 1430 **KEYNOTE LECTURE:** The Abscopal Effect of Radiation
Therapy: What is it and How Can We Use it in Kidney Cancer?
William Chu
- 1430 - 1435 Discussion and Q & A
- 1435 - 1500 The Evolving Role of Non Surgical Therapeutic Options in RCC:
1. SBRT, Anand Swaminath
2. RFA, Anil Kapoor
- 1500 - 1505 Discussion and Q & A
- 1505 - 1530 [Health Break - Sutton Foyer](#)
[Poster Viewing - Sutton Lower Foyer](#)

SESSION IV - SURVIVOR AND ADVOCACYSession Room: [Sutton B](#)

Introduction/Moderators: Georg Bjarnason, Ross Mason

- 1530 - 1615 IKCC - Current Initiatives and Future Plans
Deb Maskens
- Living with Chronic Toxicities: Healthcare Teams and
Patients Working Together
1. Physician's Input, Lori Wood
 2. A Patient's Perspective, Stephen Andrew
- 1615 - 1620 Discussion and Q & A

ABSTRACT PRESENTATIONS

- 1620 - 1700 Fusogenic Liposomes as a Novel Nanotherapy Against
Metastatic Clear Cell Renal Cell Carcinoma
Jan Rudzinski
- Determining Generalizability of the Canadian Kidney Cancer
information system (CKCis) to the Entire Canadian Kidney
Cancer Population
Camilla Tajzler
- Oncological Outcomes of Patients with Sporadic, Non-
Metastatic Renal Cell Carcinoma with Renal Vein or Inferior
Vena Cava Tumor Thrombus
Rahul Bansal
- Toward a Liquid-Biopsy-Based Precision Medicine in Renal
Cell Carcinoma Cancer Population
Kate Glennon
- 1715 - 1815 Consensus Meeting (by invitation only) - [Bristol A](#)

10th

Canadian Kidney Cancer Forum

- 1815 - 1930 Break (on own)
- 1930 - 2000 Mix & Mingle: Cocktail Reception - Sutton B
- 2000 - 2130 Banquet Dinner: Discussion and Entertainment with Your KCRNC Hosts - Sutton B
- 2130 - 2300 Networking in Hospitality Suite (1035).
(all welcome)

SATURDAY, APRIL 13, 2019

- 0730 - 0830 Buffet Breakfast - Sutton A
- 0730 - 0815 Consensus Meeting (by invitation only)
Bristol A (Breakfast served in room).

SESSION V: FUTURE OF RENAL CELL CARCINOMA

Session Room: Sutton B

Introduction/Moderators: Naveen Basappa, Stephen Pautler

- 0830 - 0850 **KEYNOTE LECTURE:**
Surgical Management of Hereditary Kidney Cancer
Syndromes
Mark Ball
- 0850 - 0855 Discussion and Q & A

KCRNC-KCC-CUASF Grant Finalists 2019 Presentation

Introduction/Moderators: Rahul Bansal, Christine Collins, Aly-Khan Lalani

- 0855 - 0905 Grant Presenter 1 - Keith Lawson
Modeling the Single-Cell Molecular Landscape of Renal Cell
Carcinoma for the Discovery of Novel Immunotherapeutic
Targets
- 0905 - 0915 Grant Presenter 2 - Cesar Monjaras-Avila
Novel 3D Kidney Cancer Model for Personalized Medicine
- 0915 - 0925 Grant Presenter 3 - Renu Jeyapala
Investigation of Novel Urinary Epigenetic circRNA Markers
for Improved Prognostication of Renal Cell Carcinoma
Among Patients Presenting with Small Renal Masses

April 11-13, 2019 • The Westin Toronto Airport Hotel

0925 - 0935 Grant Presenter 4 - Doug Cheung
Predictors of Non-Clinically Indicated Failure of Active
Surveillance in Small Renal Masses

Moderator: Christian Kollmannsberger

0935 - 1000 Joint Moderated Case Discussion Session on the Role
of CN in mRCC
Michael Blute and Laurence Albiges

1000 - 1005 Discussion and Q & A

1005 - 1030 [Exhibitor Health Break - Sutton A](#)
[Poster Viewing - Sutton Lower Foyer](#)

Introduction/Moderators: Sébastien Hotte, Anil Kapoor

1030 - 1130 IMDC: Current Questions and Development of Heng Criteria 2.0
Danny Heng

Kidney Cancer Population-Based Research: Real-Life Examples
Pierre Karakiewicz

Translational Research
Alan So

1130 - 1140 Discussion and Q & A

1140 - 1200 Progress Report, Grant Winners, and Future Discussion
Anil Kapoor

1200 [Boxed Lunch - Sutton Foyer](#)

10th

Canadian Kidney Cancer Forum

This program is an accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, reviewed and approved by the Canadian Urological Association. Completion of this program enables participants to claim a maximum of 12 hours of credit.

SUPPORTED BY

KCRNC KIDNEY CANCER RESEARCH
NETWORK OF CANADA
RRCRC RÉSEAU DE RECHERCHE SUR LE
CANCER DU REIN DU CANADA



April 11-13, 2019 • The Westin Toronto Airport Hotel

BIOGRAPHIES

Meeting Co-Chairs



Sébastien Hotte

Dr. Sébastien Hotte did his undergraduate training and went on to qualify as a physician at the University of Ottawa in 1996. He pursued internal medicine at the University of Western Ontario in London, Canada and became a fellow of the Royal College of Physicians of Canada in 2000. His subspecialty training was in Medical Oncology at Western and he received his certificate of special competence in 2001. From 2001 to 2003, Dr. Hotte completed a clinical research fellowship in Developmental Therapeutics at the Juravinski Cancer Centre and obtained a Master's Degree in Health Research Methodology from McMaster University. Dr. Hotte is currently an Associate Professor in the Department of Oncology of McMaster University and is a staff oncologist at the Juravinski Cancer Centre. One of his main research interests is in Developmental Therapeutics and Phase I trials and he is currently the Head of the Phase I Program at the Juravinski Cancer Centre. He also has clinical and research interests in genito-urinary malignancies and serves as co-chair of the GU disease site group of the Cancer Care Ontario Program for Evidence Based Care (CCO-PEBC). Lastly, he is also active in the field of translational research and has been appointed as a Scientist of the Escarpment Cancer Research Institute. He is the principle or co-author of over 110 peer-reviewed articles and over 150 original research abstracts. First and foremost, however, he is a husband and the proud father of two exceptional children, as well as a road cycling weekend warrior and Zwift aficionado.



Ricardo Rendon

Dr. Ricardo Rendon did his medical school and residency in Bogota, Colombia. He subsequently completed a clinical and research UroOncology Fellowship at the University of Toronto, Canada and a Masters in Community Health Clinical Epidemiology. He joined Dalhousie University in Halifax, Canada in 2001 where he is a Professor in the Department of Urology and the Director of Research and Clinical Trials. He is the Chair of the Genito-Urinary Cancer Site Team, Nova Scotia Health Authority Cancer Program and a Senior Investigator at the Beatrice Hunter Cancer Research Institute. Dr. Rendon is currently the Treasurer and the elect Vice-President of Education of the Canadian Urological Association. While his clinical practice focuses on all areas of urologic oncology, his research focuses on renal cell carcinoma, advanced prostate cancer and urothelial cell carcinoma. He has authored over 100 peer-reviewed manuscripts and has been particularly active in the development of clinical guidelines and national and international collaborations in kidney, bladder, upper tract urothelial cell carcinoma and prostate cancer.

BIOGRAPHIES

International Faculty



Laurence Albiges

Laurence Albiges is the Head of the Genitourinary Unit at Gustave Roussy Institute, Villejuif.

She trained as a Medical Oncologist in Paris, and joined the Genitourinary group at Gustave Roussy Institute in 2011. Her main field of interest across genitourinary tumours is new targets in renal cell carcinoma and non-clear cell renal carcinoma. She was a visiting scientist at The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Boston from 2013 to 2015, working on Papillary RCC and the Biobank of the International Metastatic RCC Database Consortium (IMDC).

Since 2015, she is in charge of the GU tumor board at Gustave Roussy and member of the GETUG board. She is an ESMO and ASCO member and was awarded several ASCO Merit Awards for her work. Since 2016, she joined the Renal Cell Carcinoma Guidelines panel of EAU.



Mark Ball

Mark Ball is a fellowship-trained urologic oncologist in the Urologic Oncology Branch of the National Cancer Institute. He received his undergraduate degree in biochemistry and molecular biology from Centre College, graduating Magna Cum Laude and Phi Beta Kappa. He received his M.D. from the Johns Hopkins University School of Medicine. He completed his internship and residency at the James Buchanan Brady Urological Institute at Johns Hopkins.

After residency, he came to the National Cancer Institute as a clinical fellow in a Society of Urologic Oncology-accredited urologic oncology fellowship where he worked in the laboratory of W. Marston Linehan.

Dr. Ball has been the recipient of several academic honors including election to the Alpha Omega Alpha honor society, outstanding laparoscopic surgeon from the Society of Laparoendoscopic Surgery, outstanding research from the Society of Urologic Oncology, recipient of an LRP award from the NIH, and multiple teaching awards at Johns Hopkins from the Department of Surgery, Department of Urology and School of Medicine.

Dr. Ball's research focuses on how tumor genetics translate into clinical behavior. He has authored over 80 peer-reviewed manuscripts and book chapters and has presented his work at multiple national and international meetings. He was recently a member of an international guideline committee on laparoscopic and robotic adrenal surgery.


Continued on next page

BIOGRAPHIES

International Faculty

He is currently investigating the role of somatic mutations in the development of kidney cancer metastasis. Recent work has also focused on the role of somatic mutations in the response to checkpoint blockade in renal cell carcinoma and how genomic features correlate with pathologic features across all urologic malignancies. He also studies the role of preoperative imaging and biopsy in risk stratification prior to surgery.

Dr. Ball maintains a busy clinical practice, specializing in the surgical treatment of all urologic malignancies and performs robotic, laparoscopic and open surgery. He has a special focus on complex partial nephrectomy for kidney tumors, partial adrenalectomy for adrenal tumors, and reoperative surgery in patients with a history of prior surgeries.



Michael Blute


Dr. Michael L. Blute received his BA Degree from the College of the Holy Cross in Worcester, and his MD Degree from Creighton University School of Medicine in 1982, graduating Magna Cum Laude. Subsequent to internship and residency in urology at the Mayo Clinic in Rochester, he remained on the staff and rose rapidly through the ranks to become the Anson L. Clark Professor and Chairman in the Department of Urology in 1999. He remained as

Chairman of the Department of Urology and on the Executive Board of the Mayo Clinic until appointed Interim Chief of Urology and Director of the Cancer Center of Excellence at the University of Massachusetts Memorial Medical Center in 2010. In April 2012, Dr. Blute was appointed Chief of Urology at The Massachusetts General Hospital in Boston and is the Walter S. Kerr, Jr. Professor of Surgery, Harvard Medical School.

Dr. Blute has had a major interest in urologic oncology and is well-known in the field of academic urology. His major areas of interest include prostate cancer, nephron-sparing surgery for kidney masses, and the management of complex renal cell and bladder neoplasms. He has been involved in phase III trials of finasteride, chemoprevention of prostatic intraepithelial neoplasia with anti-androgens, minimally invasive surgery for BPH, biomarkers in prostate cancer, and discovery of B7 family of "Check Point Inhibitor" Biomarkers in kidney cancer. He serves as a reviewer on 13 editorial boards. He serves on the AUA Renal Mass Guideline Panel and served on the American Joint Committee on Cancer. He is the recipient of the 2010 AUA Career Contribution Award. He has been honored as Department of Urology Teacher of the Year at the Mayo Clinic on several occasions. His bibliography includes 394 peer-reviewed publications, one book, and 34 book chapters.

BIOGRAPHIES

International Faculty



Brian Rini

Brian I. Rini is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A staff member of the Department of Solid Tumor Oncology of the Taussig Cancer Institute, Dr. Rini is the Leader of the Genitourinary Malignancies Program.

Dr. Rini earned his medical degree at the Ohio State University College of Medicine in Columbus, Ohio. After completing a residency program in internal medicine at University of Chicago Hospitals in Illinois, Dr. Rini was awarded a fellowship in hematology and oncology at the University of Chicago. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to Cleveland Clinic.

At Cleveland Clinic, Dr. Rini's primary research has been in renal cell carcinoma (RCC), with special focus on antiangiogenic therapy and immunotherapy. Dr. Rini's research has been published in peer-reviewed journals that include the New England Journal of Medicine, Journal of the National Cancer Institute, Journal of Clinical Oncology, Lancet and the Journal of the American Medical Association.

Certified in Medical Oncology by the American Board of Internal Medicine, Dr. Rini is active in numerous professional organizations including ASCO, the Society for Immunotherapy of Cancer (SITC) and is Chair of the Oncologic Drugs Advisory Committee (ODAC).

KCRNC Organization

KCRNC

KIDNEY CANCER RESEARCH
NETWORK OF CANADA

RRCRC

RÉSEAU DE RECHERCHE SUR LE
CANCER DU REIN DU CANADA



Anil Kapoor, KCRNC Chair

Dr. Anil Kapoor is currently Professor of Surgery (Urology & Oncology) at McMaster University/ St. Joseph's Hospital in Hamilton, Ontario, Canada. He obtained his MD from Dalhousie University. He is a Fellow of the Royal College of Physicians and Surgeons of Canada and a Diplomate of American Board of Urology. He is certified by the American Society of Transplant Surgeons, having obtained post-graduate training from the Cleveland Clinic Foundation in Renal Transplantation, Renal Vascular surgery, and GU Oncology.

Dr. Kapoor is current Head of the Genito-Urinary Oncology program at the Juravinski Cancer Centre, Co-Chair of the NCIC Kidney Cancer Disease Group, and Chair of the Kidney Cancer Research Network of Canada (KCRNC). He is also past Chair of the Medical Advisory Board (MAB) of Kidney Cancer Canada (KCC). He has published over 250 peer-reviewed papers, 5 book chapters and over 300 abstracts in the fields of genito-urinary oncology (prostate cancer and kidney cancer), kidney transplantation, and urologic laparoscopy. He is current Head of the Clinical Trials Group at the McMaster Institute of Urology (MIU) and established the Kidney Cancer Centre at McMaster University in 2009, and the Prostate Cancer Basic Science Research Collaborative in 2015.



Ranjena Maloni, KCRNC Project Manager

Ms. Ranjena Maloni is currently the Project Manager for the Kidney Cancer Research Network of Canada (KCRNC) and the Project Manager for the Canadian Kidney Cancer information system (CKCis). She is a Certified Clinical Research Professional (CCRP) and completed a postgraduate diploma in Clinical Research at Humber College. She has a BSc(Hons) from Western University in Biology and Environmental Science.

Ranjena has spent the last 10 years working in clinical research in a variety of fields, including research in Alzheimer's and diabetes. The majority of her experience has been in uro-oncology at Princess Margaret Cancer Centre, where she was the Special Projects and Clinical Trials Team lead for a large prostate cancer research group. Ranjena has been invited to give talks on the project management of investigator-initiated clinical research across Canada and in the UK. She also sits on the Board of Directors for the Canadian Pulmonary Fibrosis Foundation.

April 11-13, 2019 • The Westin Toronto Airport Hotel

KCRNC Organization

KCRNC

KIDNEY CANCER RESEARCH
NETWORK OF CANADA

RRCRC

RÉSEAU DE RECHERCHE SUR LE
CANCER DU REIN DU CANADA



Simreet Hansra-Atwal, Interim KCRNC Project Manager

Simreet Hansra-Atwal is presently the Interim Project Manager for the Kidney Cancer Research Network of Canada (KCRNC). Simreet obtained her BSc. (Hons) in Life Sciences at McMaster University.

Simreet is also a Clinical Research Coordinator for the Clinical Trials Unit at the McMaster Institute of Urology (MIU) for the past 4 years. She coordinates various trials in Kidney, Prostate and Bladder Cancer. Simreet's past experience includes her role at the Princess Margaret Cancer Centre in Toronto as a lead immune profiling technician for the Tumor Immunotherapy Program. Following which she transitioned to the position of Clinical Data Coordinator experienced with multi-centered immunotherapy clinical trials in melanoma and cervical cancer across North America.

Telephone: 647-290-9865 • Fax: 866-519-9253 • www.kcrnc.ca

April 11-13, 2019 • The Westin Toronto Airport Hotel

NOTES

NOTES

NOTES

NOTES

WE WOULD LIKE TO THANK OUR SPONSORS

PLATINUM



Bristol-Myers Squibb

GOLD



SILVER



BRONZE



CONTRIBUTOR

EMD Serono Canada

Canadian
Urological
Association

The Voice of Urology in Canada



Association
des urologues
du Canada

La voix de l'urologie au Canada

cua.org